The BTK inhibitor may be used as first-line treatment for some cases of CLL/SLL. The U.S. Food and Drug Administration (FDA) has approved pirtobrutinib (Jaypirca) for patients with chronic lymphocytic leukemia or small lymphocytic...
The new combination is approved for patients with advanced clear cell renal cell carcinoma that progressed on or after certain immune checkpoint inhibitors. The U.S. Food and Drug Administration (FDA) has approved belzutifan (Welireg)...
The new approval is for certain patients with ER-positive, HER2-negative advanced breast cancer who have received at least one line of endocrine therapy. The U.S. Food and Drug Administration (FDA) has approved imlunestrant (Inluriyo)...
Aminolevulinic acid hydrochloride is given as a topical gel in combination with light-based therapy. The U.S. Food and Drug Administration (FDA) has approved aminolevulinic acid hydrochloride (Ameluz) for the treatment of superficial basal cell...
Sevabertinib received accelerated approval as first-line treatment for some lung cancers with HER2 activating mutations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib (Hyrnuo), for the treatment of adults...
The approval marks the first ctDNA-guided cancer therapy. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to camizestrant (Etcamah) in combination with a CDK4/6 inhibitor (either abemaciclib [Verzenio], palbociclib [Ibrance], or...
Ropeginterferon alfa-2b-njft treats essential thrombocythemia by targeting blood-forming cells in the bone marrow. The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft (Besremi) injection to treat adults with a rare blood cancer,...
Therapy helps control excessive red blood cell production. The U.S. Food and Drug Administration (FDA) has approved rusfertide (Mimrylo) for adult patients with polycythemia vera, a rare, slow-growing blood cancer that causes excessive blood...
Daraxonrasib is approved for previously treated or systemic-therapy-ineligible metastatic pancreatic adenocarcinoma. The U.S. Food and Drug Administration (FDA) has approved daraxonrasib (Rasonque) for adults with metastatic pancreatic adenocarcinoma whose cancer has progressed following at...
Two zanidatamab-based regimens were approved for certain HER2-positive advanced gastric, gastroesophageal junction, or esophageal cancers. The U.S. Food and Drug Administration (FDA) has approved zanidatamab-hrii (Ziihera) as part of two first-line treatment regimens for...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More